OSE Immunotherapeutics announced on Thursday that its partner Boehringer Ingelheim has decided to continue advancing their immuno-oncology program, which will now enter phase 1b.

The German pharmaceutical group explains its decision to move into the next phase of clinical development by the positive data from the first trials conducted on its next-generation inhibitory antibody SIRPα.

In a press release, OSE points out that SIRPα is a receptor expressed by macrophages capable of recognizing, absorbing and destroying cancer cells, via an enhancement of their immune activity.

Knowing that immuno-oncology treatments currently bring lasting remission in only 15% to 20% of cancer cases, Boehringer Ingelheim explains that its ambition is to significantly increase this percentage.

On the Paris Bourse, OSE Immunotherapeutics shares advanced by just 0.1% following this announcement, but have gained nearly 54% since the start of the year.

Copyright (c) 2024 CercleFinance.com. All rights reserved.